Toggle navigation
About Us
Science & Innovation
Products and Resources
Our Responsibility
Careers
Investors
Media
Toggle navigation
Press Releases
Featured News
Press Statements
Subscribe
Media Contacts
Press Releases
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Year
All Years
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Category
All Categories
Corporate News
Product News
Vaccines News
Uncategorized
Keywords
Go
Advanced Search
Search
Search Headlines Only
Category
All Categories
Corporate News
Product News
Vaccines News
Uncategorized
From
To
Asset Types
Video
Audio
Photos
Documents
Events
Standard
Jan 25, 2023
FDA approves expanded label of Enjaymo® (sutimlimab-jome) to include long-term safety and efficacy for people with cold agglutinin disease
Jan 18, 2023
Sanofi launches first global scholarship program for students from underrepresented communities pursuing careers in healthcare
Jan 17, 2023
FDA approves Adacel® for immunization during pregnancy to help protect young infants against pertussis
Dec 21, 2022
Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine
Dupixent 300 mg weekly showed significant histological disease remission and improvement in symptoms of the disease compared to placebo
Dec 2, 2022
Sanofi to showcase new data from oncology portfolio spanning marketed products and investigational compounds at ASH 2022
Four Sarclisa® (isatuximab-irfc) oral presentations and 11 posters featuring cutting-edge investigational and marketed therapies to be presented
Show
5
10
25
50
100
per page
«
1
2
3
4
5
6
7
8
9
…
189
»
Print
Email page
RSS